Regeneron Pharmaceuticals (REGN) FCF Margin (2009 - 2026)
Regeneron Pharmaceuticals' quarterly FCF Margin came in at 23.53% in Q1 2026, down 341.0% year-on-year from 9.76% in Q1 2025, and down 0.88% quarter-over-quarter from 23.74% in Q4 2025.
Regeneron Pharmaceuticals has reported FCF Margin for 18 years, with the latest figure at 23.53% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 341.0% year-over-year to 23.53%; the trailing twelve-month figure through Mar 2026 stood at 27.57% (up 555.0% YoY), and the FY2025 full-year result was 28.45%, up 265.0% from the prior year.
- FCF Margin for Q1 2026 stood at 23.53%, down from 23.74% in the prior quarter.
- The five-year high for FCF Margin was 3919.8% in Q1 2022, with the low at 9.48% in Q2 2024.
- Average FCF Margin over 5 years is 345.89%, with a median of 26.94% recorded in 2025.
- Year-over-year, FCF Margin jumped 389632 bps in 2022 and plunged 388219 bps in 2023.
- Tracing REGN's FCF Margin over 5 years: stood at 1567.7% in 2022, then plunged by 98 bps to 24.41% in 2023, then gained by 15 bps to 28.06% in 2024, then retreated by 15 bps to 23.74% in 2025, then decreased by 1 bps to 23.53% in 2026.
- The last three FCF Margin figures came in at 23.53% (Q1 2026), 23.74% (Q4 2025), and 30.57% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -3.98% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 43.35% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 23.53% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 4.17% |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 23.53% |
| Dec 31, 2025 | 23.74% |
| Sep 30, 2025 | 30.57% |
| Jun 30, 2025 | 32.51% |
| Mar 31, 2025 | 26.94% |
| Dec 31, 2024 | 28.06% |
| Sep 30, 2024 | 23.83% |
| Jun 30, 2024 | 9.48% |
| Mar 31, 2024 | 43.83% |
| Dec 31, 2023 | 24.41% |
| Sep 30, 2023 | 21.49% |
| Jun 30, 2023 | 35.63% |
| Mar 31, 2023 | 37.61% |
| Dec 31, 2022 | 1,567.70% |
| Sep 30, 2022 | 16.57% |
| Jun 30, 2022 | 14.38% |
| Mar 31, 2022 | 3,919.80% |
| Dec 31, 2021 | 44.78% |
| Sep 30, 2021 | 95.01% |
| Jun 30, 2021 | 8.52% |
| Mar 31, 2021 | 23.48% |
| Dec 31, 2020 | 44.15% |
| Sep 30, 2020 | -17.76% |
| Jun 30, 2020 | 41.68% |
| Mar 31, 2020 | 28.88% |
| Dec 31, 2019 | 34.79% |
| Sep 30, 2019 | 24.98% |
| Jun 30, 2019 | 5.94% |
| Mar 31, 2019 | 59.94% |
| Dec 31, 2018 | 33.37% |
| Sep 30, 2018 | 20.84% |
| Jun 30, 2018 | 17.57% |
| Mar 31, 2018 | 35.69% |
| Dec 31, 2017 | 29.03% |
| Sep 30, 2017 | 23.67% |
| Jun 30, 2017 | -5.81% |
| Mar 31, 2017 | 23.16% |
| Dec 31, 2016 | 19.56% |
| Sep 30, 2016 | 43.64% |
| Jun 30, 2016 | 21.50% |
| Mar 31, 2016 | -4.92% |
| Dec 31, 2015 | 9.48% |
| Sep 30, 2015 | 65.65% |
| Jun 30, 2015 | 1.80% |
| Mar 31, 2015 | -24.83% |
| Dec 31, 2014 | 10.05% |
| Sep 30, 2014 | 11.65% |
| Jun 30, 2014 | 39.89% |
| Mar 31, 2014 | -1.81% |
| Dec 31, 2013 | 34.85% |
| Sep 30, 2013 | 10.18% |
| Jun 30, 2013 | 20.48% |
| Mar 31, 2013 | 14.79% |
| Dec 31, 2012 | 18.82% |
| Sep 30, 2012 | -2.95% |
| Jun 30, 2012 | -29.98% |
| Mar 31, 2012 | -42.32% |
| Dec 31, 2011 | -50.10% |
| Sep 30, 2011 | -54.10% |
| Jun 30, 2011 | -45.37% |
| Mar 31, 2011 | -29.18% |
| Dec 31, 2010 | 560.68% |
| Sep 30, 2010 | 2,824.11% |
| Jun 30, 2010 | -29.71% |
| Mar 31, 2010 | -1,713.73% |
| Dec 31, 2009 | -523.18% |
| Sep 30, 2009 | -27.37% |